Comparison · NCT05247489-03039f9a
Ruxolitinib 1.5% Cream BID vs Ruxolitinib 1.5% Cream BID + NB-UVB: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ruxolitinib 1.5% Cream BID vs Ruxolitinib 1.5% Cream BID + NB-UVB: Number of Participants With Any Treatment-emergent Adverse Event (TEAE). Trial comparisons, record NCT05247489-03039f9a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05247489-03039f9a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.45 | 0.258 | 0.658 | wilson | |
| Risk in group 2 | 0.6 | 0.436 | 0.744 | wilson | |
| Risk difference, group 1 minus group 2 | -0.15 | -0.39 | 0.115 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.431 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 0.545 | 0.18 | 1.66 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ruxolitinib 1.5% Cream BID than on Ruxolitinib 1.5% Cream BID + NB-UVB | 6.67 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ruxolitinib 1.5% Cream BID | Participants who achieved ≥25% improvement in Total Body Vitiligo Scoring Index (T-VASI25) at Week 12 applied ruxolitinib 1.5% cream twice daily (BID) as monotherapy through Week 48. | 9 | 20 | OG000 |
| Group 2 | Ruxolitinib 1.5% Cream BID + NB-UVB | Participants applied ruxolitinib 1.5% cream BID as monotherapy through Week 12. Participants did not achieve T-VASI25 at Week 12 and added narrow-band ultraviolet B (NB-UVB) phototherapy to their ruxolitinib 1.5% cream BID regimen. NB-UVB phototherapy was given 3 times per week through Week 48 (up to 36 weeks). Participants continued to receive ruxolitinib 1.5% cream BID through Week 48. | 21 | 35 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
- Description
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study cream. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
- Time frame
- up to approximately 52 weeks
- Population
- Full Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
- NCT number
- NCT05247489
- Phases
- PHASE2
- Conditions
- Vitiligo
- Interventions
- Ruxolitinib 1.5% cream, NB-UVB phototherapy
- Lead sponsor
- Incyte Corporation
- Results first posted
- 2025-02-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05247489?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05247489-03039f9a